In:
International Journal of Cancer, Wiley, Vol. 142, No. 5 ( 2018-03), p. 968-975
Abstract:
What's new? Inhibition of signaling by Hedgehog polypeptide and the effector protein GLI is an effective therapeutic strategy for basal cell carcinoma and medulloblastoma. The frequent development of resistance to Hedgehog pathway inhibitors (HPI), however, calls for the identification of alternative drugs. This study identifies the class I histone deacetylase inhibitor 4SC‐202 as a novel Hedgehog/GLI antagonist. A clinically suitable small molecule, 4SC‐202, showed inhibitory efficacy, blocking GLI activation and Hedgehog target gene expression, even in cells with acquired HPI resistance. The findings suggest that 4SC‐202 could be effective against Hedgehog‐driven cancers that are refractory to standard targeted therapy.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2018
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8